Abstract
Multiple myeloma is an invariably fatal cancer of plasma cells. Despite tremendous advances in treatment, this malignancy remains incurable in most individuals. We postulate that strategies aimed at prevention have the potential to be more effective in preventing myeloma-related death than additional pharmaceutical strategies aimed at treating advanced disease. Here, we present a rationale for the development of prevention therapy and highlight potential target areas of study.
Highlights
Monoclonal Gammopathy of Undetermined Significance (MGUS) Itself Is Not a Benign ConditionPre-malignant condition has been termed to be of “undetermined significance” in pre-malignant condition has been termed to be of “undetermined significance” in terms of the transition to MM, it does not mean that it is not clinically important
Compared with other solid tumor cancers that have been subject to multiple, large screening and Compared with other solid tumor cancers that have been subject to multiple, large screening prevention trials, there have yet been no efforts to try and prevent the development of multiple and prevention trials, there have yet been no efforts to try and prevent the development of multiple myeloma
We previously reviewed the literature linking obesity with the progression of multiple myeloma [55] and much attention has been given to understanding the mechanism that link these two pathologies
Summary
Pre-malignant condition has been termed to be of “undetermined significance” in pre-malignant condition has been termed to be of “undetermined significance” in terms of the transition to MM, it does not mean that it is not clinically important. Associated pathologies include sensorimotor neuropathy [15], renal Falconi syndrome [16] and and glomerulonephritis [17,18], POEMS [19], capillary leak syndrome [20], ocular disease [21,22], glomerulonephritis [17,18], POEMS [19], capillary leak syndrome [20], ocular disease [21,22], and and crystal storing histiocytosis [23,24,25], among others. There may be value in defining intervention strategies to reduce monoclonal antibody populations, beyond preventing the MGUS to MM transition.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
